Added value of concomitant systematic biopsies in predicting upgrading in patients with localized prostate cancer diagnosed by MRI-targeted biopsy: Implications for patient selection

Primary staging in patients with intermediate- and high-risk prostate cancer: Multiparametric MRI and 68Ga-PSMA-PET/MRI – What is the value of quantitative data from multiparametric MRI alone or in conjunction with clinical information?

“…Combining clinical data in conjunction with data from mpMRI in the 2018 15 Briganti model may help to classify patients at risk for nodal metastasis and therefore aid in selecting patients who would benefit from 68 Ga-PSMA-PET imaging in primary staging. [17]; 68 Ga-PSMA-PET/MRI, 68 Ga labeled radioligand targeting the prostate-specific membrane antigen PET/MRI; mpMRI, multiparametric MRI of the prostate; PI-RADS, Prostate Imaging Reporting and Data-System.…”

“…Volume (mL) was calculated as [sum of all tumor areas on the slices (cm 2 ) x slice thickness (cm)]), b) maximum tumor diameter, measured as a straight line through the longest axis of the tumor focus on an axial slice and c) maximum length of capsular contact, measured as a freehand curved line on an axial slice, d) mean ADC values and e) tumor volume on ADC maps. Additionally, probability of lymph node metastasis was calculated using the model published by Gandaglia et al (2018 Briganti model) [17] including clinical data such as PSA level, clinical stage at mpMRI, maximum tumor diameter, Gleason score and percentage of cores with clinically significant PCa.…”

“…Table 3: Diagnostic Accuracy. Diagnostic accuracy of mpMRI, 68 Ga-PSMA-PET/MRI, quantitative parameters and the 2018 Briganti model for prediction of lymph node metastasis [17] regarding stage with at least extracapsular extension ( ≥ T3) and nodal metastasis (N1) with histopathology as reference standard. AUC, Area under the Receiver Operating Characteristics Curve; d_T2, maximum tumor diameter measured on T2-weighted images; 68 Ga-PSMA-PET/MRI, 68 Ga labeled radioligand targeting the prostate-specific membrane antigen PET/MRI; ccl_T2, maximum capsular contact length measured on T2-weighted images; mpMRI, multiparametric MRI of the prostate; V_ADC, tumor volume measured on ADC maps; V_T2, tumor volume measured on T2weighted images; n/a, not available; ns, not significant.…”

“…AUC, Area under the Receiver Operating Characteristics Curve; d_T2, maximum tumor diameter measured on T2-weighted images; 68 Ga-PSMA-PET/MRI, 68 Ga labeled radioligand targeting the prostate-specific membrane antigen PET/MRI; ccl_T2, maximum capsular contact length measured on T2-weighted images; mpMRI, multiparametric MRI of the prostate; V_ADC, tumor volume measured on ADC maps; V_T2, tumor volume measured on T2weighted images; n/a, not available; ns, not significant. Briganti model for prediction of lymph node metastasis [17]. 68 Ga-PSMA-PET/MRI, 68 Ga labeled radioligand targeting the prostate-specific membrane antigen PET/MRI; mpMRI, multiparametric MRI of the prostate.…”